WSJ
08 Jul 2026, 03:44 UTC · 1h ago
AstraZeneca, Sino Biopharm Sign Up to $1.9 Billion Respiratory Drug Licensing Deal
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
WSJ
08 Jul 2026, 03:44 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Sino Biopharmaceutical will receive an upfront payment of $200 million from AstraZeneca. — Direct cash infusion provides immediate capital gain and validates the value of the company's assets.
+0.60Sino Biopharmaceutical is eligible for additional milestone payments as part of the agreement. — Creates potential for future upside and revenue growth, though contingent on specific performance goals.
+0.30Which stocks this story touches
Sino Biopharmaceutical is receiving a $200 million upfront payment and potential milestones.
Continue reading
6 related stories
Search tags
AstraZeneca is incurring a significant cash outlay for the agreement.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
2h ago
